D. Boral Capital Reaffirms “Buy” Rating for Hoth Therapeutics (NASDAQ:HOTH)

Hoth Therapeutics (NASDAQ:HOTH)‘s stock had its “buy” rating restated by investment analysts at D. Boral Capital in a note issued to investors on Wednesday,Benzinga reports. They presently have a $5.00 target price on the stock. D. Boral Capital’s price objective indicates a potential upside of 456.17% from the stock’s current price.

HOTH has been the subject of several other reports. Weiss Ratings restated a “sell (e+)” rating on shares of Hoth Therapeutics in a research note on Monday, December 22nd. Wall Street Zen upgraded shares of Hoth Therapeutics to a “sell” rating in a research report on Saturday, March 7th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $5.00.

Hoth Therapeutics Price Performance

Shares of NASDAQ:HOTH traded up $0.01 during trading on Wednesday, hitting $0.90. 46,205 shares of the company’s stock were exchanged, compared to its average volume of 553,453. The business’s 50-day simple moving average is $0.99 and its 200 day simple moving average is $1.21. The company has a market cap of $13.94 million, a price-to-earnings ratio of -0.85 and a beta of 0.50. Hoth Therapeutics has a 52-week low of $0.66 and a 52-week high of $2.12.

Institutional Trading of Hoth Therapeutics

Several hedge funds have recently made changes to their positions in HOTH. DRW Securities LLC purchased a new stake in shares of Hoth Therapeutics in the fourth quarter valued at $257,000. Geode Capital Management LLC lifted its holdings in shares of Hoth Therapeutics by 18.0% in the 4th quarter. Geode Capital Management LLC now owns 181,112 shares of the company’s stock worth $179,000 after acquiring an additional 27,577 shares during the last quarter. Kestra Private Wealth Services LLC purchased a new position in shares of Hoth Therapeutics during the 3rd quarter worth about $51,000. Lido Advisors LLC purchased a new position in shares of Hoth Therapeutics during the 3rd quarter worth about $32,000. Finally, Citadel Advisors LLC bought a new position in Hoth Therapeutics during the 3rd quarter valued at about $232,000. 7.08% of the stock is currently owned by hedge funds and other institutional investors.

About Hoth Therapeutics

Hoth Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the acquisition, licensing and development of novel therapies for dermatological, central nervous system and other debilitating conditions. The company’s strategy emphasizes in-licensing late preclinical or early clinical assets with promising pharmacological profiles and leveraging formulation science to optimize delivery. Core to its approach is the design of topical and localized administration platforms intended to enhance drug penetration, sustain release and reduce systemic exposure.

Hoth’s development pipeline encompasses multiple candidate programs addressing high-unmet-need areas such as atopic dermatitis, epidermolysis bullosa and oral mucositis.